Abivax (NASDAQ:ABVX) Shares Up 6% – What’s Next?

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) rose 6% on Wednesday . The stock traded as high as $148.83 and last traded at $146.6450. Approximately 422,088 shares were traded during mid-day trading, a decline of 52% from the average daily volume of 880,521 shares. The stock had previously closed at $138.35.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Guggenheim reaffirmed a “buy” rating and set a $175.00 price target on shares of Abivax in a report on Thursday, December 18th. Citizens Jmp raised their price objective on shares of Abivax from $114.00 to $131.00 and gave the company a “market outperform” rating in a research report on Tuesday, December 16th. Wolfe Research raised Abivax to a “strong-buy” rating in a report on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a research note on Wednesday, October 8th. Finally, Truist Financial set a $140.00 price target on Abivax in a report on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $128.73.

Abivax Stock Up 7.1%

The company has a debt-to-equity ratio of 0.03, a current ratio of 7.86 and a quick ratio of 7.86. The company has a market capitalization of $11.54 billion, a price-to-earnings ratio of -35.43 and a beta of 0.48. The firm’s 50-day simple moving average is $112.56 and its two-hundred day simple moving average is $75.18.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings results on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The firm had revenue of ($4.92) million during the quarter. Sell-side analysts predict that Abivax SA Sponsored ADR will post -2.83 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ABVX. Kennedy Capital Management LLC increased its holdings in Abivax by 7.1% during the 2nd quarter. Kennedy Capital Management LLC now owns 241,188 shares of the company’s stock valued at $1,845,000 after acquiring an additional 15,997 shares in the last quarter. Quadrature Capital Ltd acquired a new stake in shares of Abivax in the second quarter valued at approximately $148,000. Octagon Capital Advisors LP purchased a new position in shares of Abivax during the 1st quarter worth approximately $7,688,000. Saturn V Capital Management LP raised its position in shares of Abivax by 12.6% during the 2nd quarter. Saturn V Capital Management LP now owns 622,479 shares of the company’s stock worth $4,762,000 after purchasing an additional 69,553 shares during the last quarter. Finally, Allostery Investments LP lifted its stake in Abivax by 86.0% in the 1st quarter. Allostery Investments LP now owns 1,099,654 shares of the company’s stock valued at $6,873,000 after buying an additional 508,401 shares in the last quarter. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.